Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease
Alkali Therapy in Subjects With Sickle Cell Disease (SCD) - Evaluation of Efficacy, Safety, and Beneficial Effects
Sponsor: University Hospitals Cleveland Medical Center
Terminated
Poor recruitment
Other terminated trials from University Hospitals Cleveland Medical Center
- Alopecia Areata · Phase PHASE4 · Jun 2023
- Diabetes Mellitus, Type 2 · Phase PHASE4 · Jan 2023
- Cervical Spine Surgeries · Phase NA · Feb 2022
- Abdominal Surgery · Phase NA · Mar 2021
- Scar · Phase PHASE4 · Aug 2019
See all terminations from University Hospitals Cleveland Medical Center
Other Chronic Kidney Disease trials with similar outcome
A PHASE1 clinical study on Chronic Kidney Disease and Metabolic Acidosis, this trial is terminated or withdrawn. The trial is conducted by University Hospitals Cleveland Medical Center and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Apr 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospitals Cleveland Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .